
Testing Taskforce: New California COVID-19 cases, hospitalizations and deaths

6/1 9/1 12/1

3/1


6/1

Reported date



14 day average Hospitalizations

7 day Average Deaths



Average test positivity past 7 days 7.8%, Down 0.3% from last week

Cases have fallen from the peak although test positivity remains relatively high

14 day average hospitalizations have started to decline but are about 3. times the previous level

7 day average deaths remain at low levels.

For the week ending 9/3, 90% of molecular tests resulted in 24 hours and 97% of tests resulted in less than 48 hours.

Sept 9, 2022 with data as of Sept 8, 2022. <u>https://covid19.ca.gov/state-dashboard/__https://testing.covid19.ca.gov/</u> COVID-19 Cases Dashboard v2.0 - CA OpeNn Data | Tableau Pub

Variant update

- BA.5: US 87.5%, California 93.3%
- In the US and worldwide including Europe and Japan it has resulted in a surge of cases and hospitalizations
 - In Europe and in the US and Japan cases and hospitalizations and are declining
- In the US there has been a rise in deaths to ~500/day up from a prior baseline of ~250/day.
- The FDA has not reported any new failures to testing for antigen tests or molecular tests with BA.4/ BA.5.

BA.4.6

- Defining spike mutation = S:R346T
- Mutation at this position within spike previously associated with immune escape
- Growth advantage approximately 16-21% over BA.5
- Most of BA4.6 cases are in the Midwest and Northeast
- Currently 9.2% of cases in the US and 3.3% of cases in California, this has increased somewhat from two weeks ago.

BA.2.75

- First detected in India, cases of BA2.75 are rising there and it is outcompeting BA5
- BA.2.75 has multiple mutations in the spike protein of the virus which may increase infectivity and may evade the immune system.
- 98 cases detected in California, and this is the fastest growing variant in California currently.
- Preprints have found that although neutralization antibodies from vaccines or previous infection to BA.2.75 are reduced compared to the original strain, it may have less immune escape than BA.5
- We are watching this closely

Paxlovid Resistance Currently Not Seen

- Currently we are **NOT** seeing signs of mutations in SARS-CoV-2 likely to impact the effectiveness of Paxlovid
- We are monitoring the genomic sequencing data for known Paxlovid resistance mutations